249 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
If Retatrutide demonstrates a positive impact on renal function, it could represent a significant advancement in treating complex metabolic and renal diseases. As a triple GIP/GLP-1/glucagon receptor agonist, Retatrut…
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors, showing promise in weight loss and glucose control in earlier studies. If this Phase 1 trial demonstrates a significant positive impa…
The development of these incretin-based medications marks a paradigm shift in obesity treatment, offering pharmacological options with efficacy levels previously only achievable through bariatric surgery. This advance…
This case report highlights a critical safety concern for patients on tirzepatide and SGLT-2 inhibitors, emphasizing the importance of patient education regarding 'sick-day rules.' The finding that these agents can be…
This review highlights a critical gap in our understanding of optimal T2DM management during pregnancy, particularly concerning newer, highly effective antidiabetic agents. The limited evidence for novel therapies mea…
This updated prevalence data highlights the growing acceptance and utilization of effective anti-obesity medications within a critical military population. Understanding these trends is vital for resource allocation, …
The impressive 24% body weight reduction observed with retatrutide represents a significant leap forward in obesity pharmacotherapy, potentially offering efficacy comparable to bariatric surgery for some individuals. …
This study provides compelling evidence that dual and triple incretin agonists offer superior glycemic control and weight loss benefits compared to current GLP-1 receptor agonists for patients with Type 2 Diabetes. Th…
This study highlights the potential of retatrutide to not only manage blood glucose but also to directly address the underlying appetite dysregulation in type 2 diabetes and obesity. By improving appetite control and …
The designed triagonist, xGLP/GCG/GIP-32, demonstrated a distinct pharmacological profile, characterized by strong agonism at the GLP-1R and GCGR, coupled with significantly less potent activation of the GIPR (glucose…
These advancements collectively represent a significant leap forward in nephrology, offering new hope for patients with various kidney conditions. The expansion of complement inhibitors and the efficacy of GLP-1 recep…
This perspective highlights that Retatrutide exemplifies rational multi-agonist peptide engineering, signaling a paradigm shift in systems pharmacology for obesity and related conditions. Its unprecedented efficacy su…
This review underscores the transformative potential of multi-target incretin-based therapeutics for metabolic disorders. These agents could significantly expand the therapeutic arsenal for patients struggling with ty…
While the detailed quantitative results from this completed clinical trial are not yet publicly available in this record, the study successfully concluded its primary objective of assessing Tirzepatide's influence on …
The insights gained from this study are crucial for advancing personalized treatment strategies for individuals with co-occurring obesity and Binge Eating Disorder. By understanding how GLP-1 analogues interact with b…
The findings from this Phase 1 study are critically important for the future development of LY3437943. Understanding the impact of hepatic impairment on drug pharmacokinetics is essential for establishing safe and eff…
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…